Therapy Areas: Vaccines
Australia's CSL reaffirms commitment to manufacturing 50 million doses of AstraZeneca's COVID-19 vaccine
14 October 2021 -

Australian biotechnology company CSL Ltd (ASX:CSL) has said that it is committed to its agreement for the production of about 50 million doses of British pharmaceutical company AstraZeneca's (LON:AZN) COVID-19 vaccine into 2022, Reuters news agency reported on Thursday.

This follows a media report that AstraZeneca's Vaxzevria vaccine would no longer be manufactured in Australia due to demand for vaccines of Pfizer (NYSE:PFE) and Moderna (Nasdaq:MRNA).

CSL stated that over 20 million doses of the vaccine have already been produced and it is expected that the remaining production will be completed early next year.